Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 2

2(28.6%)

Early Phase 1

1(14.3%)

7Total

N/A(4)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04374305Phase 2Recruiting

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Role: collaborator

NCT01885767Recruiting

Neurofibromatosis (NF) Registry Portal

Role: lead

NCT02718131Not ApplicableTerminated

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

Role: collaborator

NCT00863122Early Phase 1Completed

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Role: collaborator

NCT02811718Not ApplicableCompleted

Resiliency Training for Patients With NF2 Via Videoconferencing With Skype

Role: collaborator

NCT02387177Not ApplicableCompleted

Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype

Role: collaborator

NCT01419639Phase 2Completed

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Role: collaborator

NCT02298270Not ApplicableCompleted

Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype

Role: collaborator

All 8 trials loaded